Full Breakdown
Grail’s Galleri Test Faces FDA Advisory Vote Amid Controversy Over Trial Results and Medicare Coverage
By Drooid · · How we work
FDA Advisory Panel Recommends Approval
An FDA advisory committee voted unanimously that Grail’s Galleri blood test is safe, 6-4 that it is effective, and 7-2 that its benefits outweigh its risks. The panel’s recommendation comes despite the pivotal UK-NHS trial failing to show a reduction in late-stage cancer diagnoses, the surrogate endpoint used in the study. The FDA itself has not yet issued a final decision.
Legislative Context and Potential Medicare Coverage
The Medicare Multi-Cancer Early Detection Screening Coverage Act, signed into law earlier this year, mandates Medicare coverage for any multicancer screening test that receives FDA approval, bypassing the usual U.S. Preventive Services Task Force review. The law enjoyed bipartisan support because “cancer” and “early detection” carry strong political appeal. If the FDA grants full approval, Medicare would cover Galleri for adults 50 and older, and private insurers are expected to follow suit.
Trial Findings and Evidence Gaps
Grail’s partnership with England’s National Health Service enrolled roughly 140,000 participants to assess how many patients were diagnosed with late-stage cancer. The study did not measure cancer-specific mortality, the gold-standard outcome for screening efficacy. Results showed no decrease in late-stage disease, providing no evidence that the test will achieve the 25 % mortality reduction modeled by Grail investigators. Critics note that earlier ovarian-cancer screening trials similarly lowered late-stage diagnoses without improving survival.
Market Reaction and Investor Perspective
Shares of Grail have been volatile. After a profit-taking sell-off on a Tuesday, the stock fell 10.9 %, while the year-to-date gain remains around 60 %. CNBC’s Jim Cramer described the stock as “speculative” and suggested investors start with a small position and add on weakness. He also noted that the test is already selling without broad insurance coverage, but a full FDA approval could be a “game-changer.” The test’s list price ranges from $500 (the Medicare benchmark for Cologuard) to $949. With more than 120 million Americans over age 50, annual screening could cost $60-$100 billion. Grail trades at roughly 34 times sales, a valuation Cramer called “very expensive.”
Official Statements & Responses
The advisory panel’s vote numbers (6-4 on effectiveness, 7-2 on benefit-risk balance) constitute the primary official response to the trial data. The National Cancer Institute has announced plans for a large randomized trial that will use cancer-specific death as the primary endpoint, raising questions about whether early Medicare coverage could impede enrollment in that study.
Conflicting Reports & Gaps
StatNews analysts argue that the trial’s surrogate endpoint and negative result do not justify approval or imminent Medicare coverage, emphasizing the lack of mortality evidence. In contrast, the FDA advisory panel’s majority vote on effectiveness and Cramer’s bullish market outlook suggest confidence in the test’s clinical value despite the same data. No consensus exists on whether the test will meaningfully reduce cancer deaths.
Verbatim Quotes
- “The FDA's advisory vote makes it seem likely that Grail's test will get full FDA approval,” — Jim Cramer
What’s Next
The FDA is expected to issue a final decision early next year. The National Cancer Institute’s upcoming mortality-focused trial will provide the definitive evidence many clinicians and policymakers say is still missing. If the FDA grants approval, Medicare coverage will begin under the 2024 Act, potentially adding billions in annual spending.